Clinical Trial Results: A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM) [Phase 2]

View source ↗

Summary

Phase 2 proof-of-concept study evaluating the efficacy and safety of Daxdilimab in dermatomyositis and anti-synthetase inflammatory myositis has completed with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anti-synthetase Inflammatory Myositis
• Dermatomyositis

Drugs mentioned

• DAXDILIMAB (daxdilimab)

Snippet

Sponsor: Amgen | Conditions: Idiopathic Inflammatory Myositis | Phase 2 | Status: COMPLETED | Results posted: 2026-08-25